Research Analysts Set Expectations for ACRV Q3 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities researchers at HC Wainwright reduced their Q3 2025 EPS estimates for shares of Acrivon Therapeutics in a research note issued on Thursday, August 14th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.55) per share for the quarter, down from their prior forecast of ($0.52). The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($2.23) EPS, FY2026 earnings at ($2.75) EPS, FY2027 earnings at ($1.88) EPS, FY2028 earnings at ($1.17) EPS and FY2029 earnings at ($0.79) EPS.

Several other equities analysts have also recently issued reports on ACRV. Piper Sandler initiated coverage on Acrivon Therapeutics in a research report on Monday, May 5th. They set an “overweight” rating and a $6.00 price target on the stock. Oppenheimer lowered their target price on Acrivon Therapeutics from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Jones Trading reiterated a “hold” rating on shares of Acrivon Therapeutics in a research report on Friday, May 16th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Acrivon Therapeutics presently has an average rating of “Buy” and a consensus target price of $17.57.

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV opened at $1.35 on Monday. The stock has a market cap of $42.47 million, a price-to-earnings ratio of -0.60 and a beta of 1.65. Acrivon Therapeutics has a 12 month low of $1.05 and a 12 month high of $10.16. The stock’s 50 day moving average price is $1.29 and its 200 day moving average price is $2.49.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.02.

Hedge Funds Weigh In On Acrivon Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ACRV. Quadrature Capital Ltd acquired a new stake in Acrivon Therapeutics during the 2nd quarter worth about $26,000. Nuveen LLC purchased a new position in shares of Acrivon Therapeutics in the first quarter worth approximately $27,000. Wealthedge Investment Advisors LLC acquired a new stake in shares of Acrivon Therapeutics during the fourth quarter valued at approximately $65,000. Invesco Ltd. acquired a new stake in shares of Acrivon Therapeutics during the first quarter valued at approximately $72,000. Finally, Corton Capital Inc. purchased a new stake in shares of Acrivon Therapeutics in the 4th quarter valued at approximately $73,000. Institutional investors and hedge funds own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.